Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 252Gynecologic 10Tumor-Agnostic 3Thoracic 2Other 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Neoplasms 2Neoplasm Metastasis 2

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Anastrozole × Tumor-Agnostic × Clear all
NCT01602380 2026-02-27

FALCON

AstraZeneca

Phase 3 Completed
462 enrolled 20 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01197170 2021-01-22

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

M.D. Anderson Cancer Center

Phase 1 Completed
277 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02093351 2019-10-02

To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer

AstraZeneca

Phase 1 Completed
79 enrolled 35 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡